Leerink Swann Starts Cyclacel Pharmaceuticals (CYCC) at Outperform; Multiple Opportunities Create Attractive Entry Point
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Swann initiates coverage on Cyclacel Pharmaceuticals (NASDAQ: CYCC) with an Outperform. PT $3.
Leerink analyst says, "With a foundation of targeting cell cycle pathways for the treatment of cancer, CYCC has recently advanced to become a "late stage" biotechnology company following the initiation of the pivotal Phase III SEAMLESS for lead clinical candidate, sapacitabine, in acute myeloid leukemia (AML) under an SPA. We see several clinical and corporate events over the next few months to years clarifying the possible commercial opportunities for the company's pipeline candidates, and potentially unlocking value in CYCC shares."
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $1.20 yesterday.
Leerink analyst says, "With a foundation of targeting cell cycle pathways for the treatment of cancer, CYCC has recently advanced to become a "late stage" biotechnology company following the initiation of the pivotal Phase III SEAMLESS for lead clinical candidate, sapacitabine, in acute myeloid leukemia (AML) under an SPA. We see several clinical and corporate events over the next few months to years clarifying the possible commercial opportunities for the company's pipeline candidates, and potentially unlocking value in CYCC shares."
For more ratings news on Cyclacel Pharmaceuticals click here and for the rating history of Cyclacel Pharmaceuticals click here.
Shares of Cyclacel Pharmaceuticals closed at $1.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
- Axis Capital Limited Assumes Jubilant Foodworks Ltd (JUBI:IN) at Reduce (3)
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
